GlassScriptPhysician profile
Patrice Alves
NPI 1437132966
$15,093.21
in general payments reported to CMS, 2019-2025
58 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,371 · 2020: $2,051 · 2021: $2,486 · 2022: $2,756 · 2023: $2,770 · 2024: $1,249 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,429.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,909.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,654.54 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Astrazeneca Pharmaceuticals LP | $1,533.52 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Lilly USA, LLC | $1,324.40 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $1,284.05 | 2019-2025 | Repatha, Otezla, Evenity |
| Daiichi Sankyo INC. | $969.97 | 2020-2025 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $848.27 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Merck Sharp & Dohme LLC | $551.26 | 2019-2024 | Belsomra, Steglatro, Steglujan |
| Janssen Pharmaceuticals, INC | $508.01 | 2019-2023 | Xarelto |
| Pfizer INC. | $450.08 | 2019-2025 | |
| Glaxosmithkline, LLC. | $405.94 | 2020-2025 | Shingrix, Arexvy, Penmenvy |
| Takeda Pharmaceuticals U.S.A., INC. | $320.27 | 2021-2023 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $283.44 | 2020-2021 | |
| Astellas Pharma US INC | $255.83 | 2019-2022 | |
| Esperion Therapeutics, INC. | $252.36 | 2020-2024 | Nexletol |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrice Alves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.